Takeda's $64 Billion Offer Bolstered by Shire's Results
Shire Plc’s results topped expectations for its latest quarter, bolstering Takeda Pharmaceutical Co.’s case in selling its $64 billion takeover offer to investors. Revenue at Shire totaled about $3.8 billion in the first three months of the year, more than the $3.7 billion analysts expected, driven by growth in the company’s immunology drugs. About 72 percent of Shire’s sales came from its rare-disease division, a business coveted by Takeda.